Background: A marginal interaction between sex and the type of alkylating agent was observed for event-free survival in the Euro-EWING99-R1 randomized controlled trial (RCT) comparing cyclophosphamide and ifosfamide in Ewing sarcoma. To further evaluate this interaction, we performed an individual patient data meta-analysis of RCTs assessing cyclophosphamide versus ifosfamide in any type of cancer.
INTRODUCTION
The Euro-E.W.I.N.G.99-R1 randomized trial (EE99-R1, NCT000 20566) 1 [VAI]) as maintenance treatment in localized standard-risk Ewing sarcoma. We observed that sex marginally modified the treatment effect on event-free survival (EFS, interaction test, P = 0.083): in males, VAC was associated with poorer EFS than VAI with a hazard ratio (HR) (VAC/VAI) = 1.34 (95% CI = 0.96-1.86), whereas VAC was slightly better than VAI in females with an HR = 0.83 (95% CI = 0.54-1.28). 2 Epidemiological studies have reported a higher incidence and mortality among men than women. 3, 4 Registry-based survival analyses adjusted for age and disease stage have also shown that survival tends to be worse in males in various cancers. 4, 5 Moreover, numerous clinical trials of cancer patients report a worse prognosis in males in most studies. [6] [7] [8] [9] [10] There are also sex differences in chemotherapy-related toxicity, especially with alkylating-based chemotherapy, with higher toxicity rates in females, especially hematological toxicity. 2, [10] [11] [12] [13] [14] Some of these findings regarding efficacy and toxicity can be explained by pharmacokinetic differences in drug metabolism (e.g., different expression of liver metabolizing enzymes according to sex), leading some authors to propose sex-based dose adaptations. [15] [16] [17] [18] However, no interaction between the type of alkylating agent (cyclophosphamide or ifosfamide) and sex on efficacy and acute toxicity outcomes was reported before the EE99-R1 trial. In an attempt to confirm the EE99-R1 observation, we conducted a Meta-Analysis on Interaction between Alkylating agents and GEnder (MAIAGE) of randomized controlled trials (RCTs) comparing cyclophosphamide versus ifosfamide to confirm whether or not the effect of these two treatments differs between males and females.
MATERIALS AND METHODS

Trial selection
To identify an independent validation set for the EE99-R1 data, we undertook a bibliographic search of clinical trials randomizing cyclophosphamide versus ifosfamide (possibly in addition to other drugs but these drugs had to be identical in both arms) in both sex, without restriction on patient age and type of cancer. We searched Cyclophosphamide and ifosfamide could have been administered either as a single drug or combined with other drugs, but in the latter case, the only difference between the two arms had to be cyclophosphamide and ifosfamide. Differences in the dosage and infusion duration of cyclophosphamide and ifosfamide were allowed across studies. RCTs comparing only one course of cyclophosphamide or ifosfamide were not eligible. Moreover, RCTs for which individual patient data concerning survival and toxicity were not available were excluded.
Data extraction and trial quality assessment
Individual patient data were collected for each trial: sex, date of birth, allocated treatment, date of randomization, date of first event, type of first event (progression, relapse, secondary malignancy, death), date of last follow-up or death, survival status, and cause of death (if applicable). We also collected acute toxicity data for leucopenia/neutropenia, thrombocytopenia, infection, mucositis and diarrhea, renal, liver, cardiac, skin, and central and peripheral neurologic toxicities during the randomized period with the grade according to the NCI-CTCAE (Common Terminology Criteria for Adverse Events) grading system. Individual anonymous data were centrally collected (BF and MCLD) and checked using a standard procedure (See Supplementary Methods S1). We noted missing data, data validity, randomization integrity, and follow-up of patients between the two arms. 19 
Statistical analysis
The primary endpoint was progression-free survival (PFS), defined as the time from randomization to progression, recurrence or death from any cause, whichever occurred first. The secondary endpoint was overall survival (OS), defined as the time from randomization to death from any cause. Patients who had no events were censored at the date of the last follow-up. Analyses were performed on an intention-to-treat basis.
The validation set was analyzed using a multivariable Cox model, stratified by trial and sex, and including treatment (cyclophosphamide vs. ifosfamide) and age as main fixed effects. Age was divided into three categories (<12, [12] [13] [14] [15] [16] [17] [18] and >18 years) with selected cut-offs close to those defining the different pubertal status for males and females. The HR of the treatment effect by sex was measured by an interaction term ("one-stage" model). 20 Sensitivity analyses were also performed (see Supplementary Methods S2).
The heterogeneity test was assessed by Cochran's Q-statistics and I². 21, 22 In addition, we performed an exploratory analysis on all RCTs, that is, EE99-R1 and the validation set. Stratified PFS curves were used to calculate the absolute difference at 5 years. 23 All statistical analyses performed for the validation set were also repeated on the pooled dataset. To explore heterogeneity of the treatment-by-sex interaction term across all trials and age categories, a three-order interaction term was included, with the relative two-order interactions terms.
For each type of acute toxicity, the maximum grade was computed for each patient and dichotomized as follows: hematologic toxicity (<, ≥grade-4); mucositis (<, ≥grade-3); diarrhea (<, ≥grade-3); and infection, renal, liver, cardiac, skin, central, and peripheral neurologic toxicities (<, ≥grade-2). The main safety analysis included toxicities that had occurred in at least five males and females in each trial arm to allow interaction analyses: leucopenia/neutropenia, infection, renal toxicity.
For each type of toxicity, we estimated the treatment-by-sex interaction term using a logistic regression model stratified by trial and including age category, sex, treatment (main fixed effects), and treatmentby-sex interaction. We assessed the heterogeneity of the interaction across trials using a three-order interaction term between treatment, sex, and trial. 
RESULTS
Trials description
In addition to the EE99-R1 trial, 1 we identified three trials (EICESS92, 25 IRS-IV, 26 and an EORTC randomized phase-II trial in soft tissue sarcomas 1 ) among 380 references of published papers and 37 studies registered on ClinicalTrials.gov (Fig. 1 ). The EORTC trial was excluded because the individual patient data (survival and toxicity) were not available. We also excluded three randomized trials conducted exclusively in women (breast cancer, 28 ovarian epithelial cancer, 29 and endometrial adenocarcinoma 30 ). Regarding the IRS-IV trial which compared three parallel groups, we considered the VAI and VAC arms, and excluded the third arm (vincristine-ifosfamideetoposide arm). Actualization of the literature search in November 2016 did not identify any other trial fulfilling the inclusion criteria.
The three RCTs retained were high-quality phase III trials (See Supplementary Methods S1) comparing cyclophosphamide to ifosfamide in multidrug combinations administered as first-line treatment (Table 1) . Sex was considered as a stratification variable in these three trials. The dose ratio of ifosfamide/cyclophosphamide ranged from 4 to 5. In total, 1,528 patients were included, 773 in the cyclophosphamide arm and 755 in the ifosfamide arm. The EE99-R1 trial represented 56% of the total number of patients. These trials were all conducted in sarcomas (Ewing sarcoma, rhabdomyosarcoma, and undifferentiated sarcomas). They included children, adolescents, and young adults, aged <15 years in 66% of the patients (Table 2) .
Survival analysis
With a median follow-up of 6.8 years (Q1-Q3, 4.5-8.9) (5.9 and 8.0 years in EE99-R1 and the validation set containing EICESS92
and IRS-IV, respectively), we observed 424 disease failures (i.e., PFS events: 224 and 200 in EE99-R1 and the validation set, respectively; progression or relapse in 395 patients and death as first event in 29, including six treatment-related deaths, nine from disease progression, nine other causes, and five unknown causes). There were 325 deaths overall (171 and 154 in EE99-R1 and the validation set, respectively).
The estimated treatment-by-sex interaction on PFS in EE99-R1 (HR = 1.73, 95% CI = 1.00-3.00, P-value = 0.051) was not replicated in the validation set (n = 672) using the one-stage model (EICESS92+IRS-IV, HR = 0.97, 95% CI = 0.55-1.72, P = 0.93; Fig. 2 ), with no heterogeneity between both trials (P = 0.62). Interaction estimates were very similar in the sensitivity analyses (Table 3 ). In the same way, the estimated treatment-by-sex interaction in EE99-R1 for OS (HR = 1.85, 95% CI = 0.98-3.48, P = 0.056) was not replicated in the validation set (HR = 1.00, 95% CI 0.52-1.92, P = 0.99; Supplementary Fig. S1 ).
When the three RCTs were pooled, the estimated 5-year absolute PFS benefit associated with ifosfamide compared to cyclophosphamide was greater among males +6.0% (73.7% vs. 67.9%) than females (+0.2%, 75.2% vs. 75.0%; Fig. 3 ). However, the overall estimate of treatment-by-sex interaction was not statistically significant (HR = 1.31, 95% CI = 0.89-1.95, P = 0.17). Although a significant treatment-by-sex interaction was observed in EE99-R1 (P = 0.051), this interaction was not statistically different to interaction terms estimated in EICESS92 and IRS-IV trials (P = 0.36; Fig. 2 ). This interaction estimate did not vary across age categories (P = 0.88, Supplementary Fig. S2 ). The sensitivity analyses yielded similar results (last column, Table 3 ). For OS (Supplementary Fig. S3 ), the pooled estimate of the treatment-by-sex interaction was not statistically significant (HR = 1.37, 95% CI = 0.87-2.15, P = 0.17). We observed neither heterogeneity across trials (P = 0.35, Supplementary Fig. S4 ) nor across age categories (P = 0.64, Supplementary   Fig. S4 ). Stable results were observed in the sensitivity analyses (Table 3 ).
Toxicity analysis
The frequencies of severe acute toxicities by sex and treatment arm are shown in Supplementary Patients with either a good histologic response to preoperative treatment (<10% cells), or a small tumor (<200 mL) resected at diagnosis or with radiotherapy alone as local treatment.
c After exclusion of patients with completely resected paratesticular tumors, completely resected or microscopic residual disease of orbit or eyelid tumors, preexisting renal abnormalities. 
TA B L E 2 Characteristics of randomized patients in each trial included in the meta-analysis
DISCUSSION
Using an independent validation set of two RCTs (EICESS92 and IRS-IV), we did not replicate the treatment-by-sex interactions observed in the EE99-R1 trial on PFS and OS. No significant interactions were observed when the three trials were pooled, with no significant heterogeneity across age and trials. Similarly, we did not identify any treatment-by-sex interaction on leucopenia/neutropenia, infection, and renal toxicity. Cyclophosphamide was significantly more hematotoxic (leucopenia/neutropenia and infections) than ifosfamide. We also observed more hematotoxicity in women than in males regardless of treatment arm.
This individual patient data meta-analysis is the first to assess a potential interaction between the type of alkylating agent and sex.
Based on high-quality RCTs comparing cyclophosphamide to ifosfamide in both sex, with a total number of patients exceeding 1,500
and long follow-up, it provides an unbiased estimate of the treatmentby-sex interaction. Finally, even though the search was not restricted to age or to a specific type of cancer, these three trials included mainly pediatric and young adult patients, with Ewing sarcoma or rhabdomyosarcoma under first-line treatment. This probably reduces F I G U R E 2 Forest plot of the hazard ratios (HRs) of progression-free survival in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex using fixed effects model. HRs given on the right side represent the HR of the treatment-by-sex interaction (HRCyclo/Ifo in males/HRCyclo/Ifo in females) estimated independently for each trial, in the validation set and in the pooled dataset, by the one-stage model, stratified by trial and sex, and including treatment (cyclophosphamide vs. ifosfamide) and age (<12, 12-18, and >18 years) as the main fixed effects. The heterogeneity of the interaction across trials was assessed using a three-order interaction term. The center of each square represents the HR for individual trials and for the validation set (EICESS92 + IRS-IV) and the corresponding horizontal line its 95% confidence interval (CI). The area of squares is proportional to the amount of information obtained from the trial. The center of the black diamond represents the overall HR and the extremities of the diamond represent its 95% CI, both estimated from the pooled dataset
TA B L E 3
Estimate of the hazard ratio of the treatment-by-gender interaction term for progression-free survival and overall survival for EE99-R1 (training set), EICESS92 + IRS-IV (validation set), and the pooled dataset in the main and sensitivity analyses sources of heterogeneity across trials (e.g., pharmacodynamic differences and co-morbidity).
The EORTC trial 27 that randomized cyclophosphamide and ifosfamide as a single drug in advanced or metastatic soft-tissue sarcomas (n = 135 patients) was not included in the MAIAGE study due to the lack of availability of individual survival or toxicity data after contacting the principal investigator. This study reported lower response rates in the cyclophosphamide arm than in the ifosfamide arm, especially in males (observed response rate of 0% and 11% in males treated with cyclophosphamide and ifosfamide, respectively, and 17% and 23% in females). Based on these data, we did not observe any significant heterogeneity of the treatment effect between sexes (interaction test: P = 0.12). In the three other randomized trials excluded (because they were based on women only, see Supplementary Table S2) , [28] [29] [30] a better prognosis was reported in two, in subgroups of women treated with ifosfamide, 29, 30 whereas the difference was not significant in the third trial. 28 Our study had some limitations. First, none of the trials analyzed were initially designed to study a treatment-by-sex interaction. Due to the observed number of events in each trial and when pooled, the F I G U R E 3 Stratified progression-free survival (PFS) curves according to sex and alkylating agent (cyclophosphamide or ifosfamide) when the three RCTs were pooled (n = 1,528). The 5-year absolute PFS benefit associated with ifosfamide (Ifo) compared to cyclophosphamide (Cyclo) was estimated at 6% in males (73.7% vs. 67.9%), whereas females receiving ifosfamide or cyclophosphamide had similar PFS (75.2% vs. 75.0%, difference = 0.2%) analyses could be underpowered to test the interaction with a standard statistical level (P < 0.05), let alone to detect heterogeneity of the treatment-by-sex interaction across trials (e.g., infection analysis with marginal heterogeneity across trials, P = 0.12). Although we did not validate a treatment-by-sex interaction on efficacy outcomes, our results do not conclusively rule out the existence of an interaction.
Second, in addition to the index trial, we identified only two other RCTs, which together contributed less than 50% of the total number of patients. We did not identify any other study comparing cyclophosphamide and ifosfamide, hence there is a paucity of independent trials. Finally, differences in population characteristics and in drug combinations in the backbone chemotherapy could impact the consistency of the estimates of treatment-by-sex interaction. Indeed, (i) rhabdomyosarcoma patients in IRS-IV were younger than Ewing sarcoma patients from the other two trials, and (ii) all IRS-IV patients received four additional courses with cyclophosphamide after the first eight courses allocated by randomization; in contrast, all patients also received ifosfamide as induction chemotherapy before randomization in both Ewing sarcoma trials.
Our findings concerning acute toxicity are consistent with previous reports in sarcoma and lymphoma patients treated with alkylating agents. [10] [11] [12] [13] [14] Differences in cytochrome P450 mediated drug metabolism between sexes could explain these results. Cyclophosphamide and ifosfamide are oxazaphosphorine alkylating prodrugs that are metabolized via different P450-catalyzed pathways: (i) 4-hydroxylation produces active alkylating agents and urotoxic acrolein via CYP2B6 for cyclophosphamide and CYP3A4 and CYP3A5 for ifosfamide, and (ii) N-dechloroethylation generates inactive metabolites and nephro-and neurotoxic chloroacetaldehyde via CYP3A4 for cyclophosphamide and, to a much greater extent, CYP3A4 and CYP2B6 for ifosfamide. [31] [32] [33] Greater activity of CYP3A4 and CYP2B6 has been reported in females resulting in higher concentrations of toxic chloroacetaldehyde after ifosfamide infusion and consequently in a possible higher risk of severe neurotoxicity in females. [34] [35] [36] However, no cytochrome P450 related difference in hematologic toxicity between sexes has previously been reported.
In conclusion, our meta-analysis did not show that the treatment effect of cyclophosphamide versus ifosfamide is influenced by sex for either efficacy or toxicity. Therefore, recommending the choice of alkylating agent should not be based on sex in children and young adults treated for sarcoma. Additional studies would be useful for longterm follow-up including fertility outcomes. 
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